Variant Bio Appoints Craig T. Basson as Chief Medical Officer to Accelerate Genomics-Driven Drug Discovery
核心洞察
Variant Bio (搜索), a genomics-driven AI drug discovery company, has appointed Craig T. Basson (搜索), MD, PhD, as Chief Medical Officer and President of R&D to advance clinical programs.
Dr. Basson brings over 25 years of leadership experience, including successful development of multiple therapies at Novartis such as Entresto, Leqvio, and Ilaris.
The appointment positions Variant Bio (搜索) to accelerate translation of genetic discoveries into differentiated clinical programs using their proprietary Inference AI platform.
Variant Bio (搜索), a genomics-driven AI drug discovery company, announced the appointment of Craig T. Basson (搜索), MD, PhD, as Chief Medical Officer and President of R&D. The strategic hire brings more than 25 years of leadership experience across academic medicine, global pharmaceutical development, and biotechnology, with deep expertise in cardiovascular and metabolic disease (搜索), human genetics, and translational science.
Proven Track Record in Drug Development
Dr. Basson most recently served as Chief Medical Officer at Bitterroot Bio (搜索), a cardio-immunology company, where he built the clinical development strategy from inception and rapidly advanced the lead program through Phase 1 and into Phase 2 clinical testing. Prior to that role, he was Co-Chief Medical Officer of Boston Pharmaceuticals, helping scale the company from an early-stage organization into a multi-program clinical biotech, overseeing development across general medicine and oncology while working closely with the U.S. Food and Drug Administration.
His most significant pharmaceutical experience came during a decade at Novartis, where he joined in 2010 as Global Head of Cardiovascular Translational Medicine and later led the combined Cardiovascular and Metabolism early development organization. His teams supported more than ten successful proof-of-concept studies and advanced multiple therapies through development, including Entresto, Leqvio, Ilaris, and pelacarsen. He also contributed to major outcomes programs, including the landmark CANTOS trial.
Academic Foundation and Research Excellence
Dr. Basson earned both his MD and PhD at Yale University and completed medical training at Johns Hopkins University and Brigham and Women's Hospital. He spent 14 years at Weill Cornell Medicine leading research on the genetic basis of cardiovascular disease (搜索), with contributions recognized by election to the American Society of Clinical Investigation and designation as an Established Investigator of the American Heart Association.
Strategic Role at Variant Bio
At Variant Bio (搜索), Dr. Basson will direct research and lead clinical strategy and development as the company advances therapeutics informed by their Inference AI discovery platform and insights from studies with populations around the world. The company develops life-saving therapies by studying the genes of people with exceptional health-related traits, identifying communities with unique genetic architectures and outlier phenotypes to create novel human genetic evidence for programs with breakthrough potential across multiple therapeutic areas.
"Craig's career uniquely spans deep human genetics, rigorous clinical science, and successful drug development at scale," said Andrew Farnum (搜索), Chief Executive Officer of Variant Bio (搜索). "His leadership and experience translating genetic insights into medicines will be instrumental as we move our programs into the clinic."
Vision for Genomics-Driven Discovery
Dr. Basson expressed enthusiasm for the company's approach to drug discovery. "Variant Bio (搜索)'s ability to uncover actionable insights from large-scale human genomics represents a powerful opportunity to improve how medicines are discovered and developed. I'm excited to help translate this science into meaningful benefits for patients."
The company's research is powered by its proprietary Inference platform, which integrates across deep phenotyping and multi-omic data using statistical genetics and AI/ML approaches to identify and validate therapeutic targets. Variant Bio (搜索) launched an unprecedented benefit-sharing program in 2020, pledging tangible benefits that directly impact the communities it partners with throughout the world.